Country
Clinical Trials in Laos
Studies with at least one site in Laos. Open a trial for its sites in Laos, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 13Infectious Disease, Therapeutics
Rickettsia Clearance Study
Murine typhus is a disease caused by Rickettisa typhi, an obligate intracellular bacterium transmitted by rodent fleas. The disease has a worldwide distribution; however the true burden is unknown, related to its non-specific…
- Trial name
- RiCS (NCT05972772)
- Testing
- Doxycyclin, Azithromycin
- Where
- 2 sites in Laos
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Melioidosis
Environment, Pathogens, and Host Interactions in Melioidosis
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
- Trial name
- DeEPH (NCT07345910)
- Where
- 3 sites in Cambodia, Laos and 1 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Opisthorchis Viverrini
Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini
This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini.
- Trial name
- ADORA-VI (NCT07262814)
- Testing
- Apraziquantel
- Where
- Laos
- Volunteers
- 125 people
- Sponsor
- Jennifer Keiser
Smoking Cessation, HIV
Smoking Cessation Program for Lao People With HIV
Tobacco use remains the leading modifiable risk factor for preventing cancer globally, particularly among people with HIV (PWH). In Laos, 61-80% of male PWH and 3-10% of female PWH smoke cigarettes.
- Trial name
- I-STOP (NCT07014605)
- Testing
- Smoking Cessation Self Help Guide, Smartphone-delivered Automated Messaging
- Where
- 2 sites in Laos
- Volunteers
- 1,200 people
- Sponsor
- University of Oklahoma
Influenza, Influenza, Human
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity.
- Trial name
- AD ASTRA (NCT05648448)
- Testing
- Oseltamivir, Favipiravir, Zanamivir
- Where
- 4 sites in Brazil, Laos and 2 more
- Volunteers
- 3,000 people
- Sponsor
- University of Oxford
COVID-19
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity.
- Trial name
- PLATCOV (NCT05041907)
- Testing
- Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
- Where
- 7 sites in Brazil, Laos and 3 more
- Volunteers
- 3,800 people
- Sponsor
- University of Oxford
Hypoxemia, Morality
Health Systems and Policy Contexts of Medical Oxygen
This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies.
- Conditions
- Hypoxemia, Morality, Pneumonia
- Trial name
- MOXY-HSP (NCT06169514)
- Testing
- No intervention
- Where
- 6 sites in Cambodia, Laos and 4 more
- Volunteers
- 1 people
- Sponsor
- Murdoch Childrens Research Institute
Acute Febrile Illness
Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia
This prospective multi-site observational study aims to describe causes and clinical outcomes of acute febrile illness as well as host biomarkers in patients aged >28 days residing in rural areas in Laos, Myanmar, Thailand, the…
- Trial name
- SEACTN-WP-B (NCT04629053)
- Where
- 4 sites in Bangladesh, Laos and 1 more
- Volunteers
- 7,200 people
- Sponsor
- University of Oxford
Cigarette Smoking
Mobile Health Technology for Personalized Tobacco Cessation Support in Laos
In Lao People's Democratic Republic (Lao PDR), 51% of adult men and 7% of adult women smoke tobacco. The development and evaluation of sustainable tobacco cessation interventions suitable for widespread adoption in nations such…
- Trial name
- SupportLaos (NCT05233228)
- Testing
- Nicotine patch, Self-help materials (to support smoking cessation), Smartphone-based automated treatment for smoking cessation
- Where
- 2 sites in Laos
- Volunteers
- 500 people
- Sponsor
- University of Oklahoma
Completed, with results posted
All –Strongyloides Stercoralis Infection
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia.
- Trial name
- StrongMoxi (NCT04056325)
- Testing
- Moxidectin, Ivermectin
- Where
- Laos
- Volunteers
- 617 people
- Sponsor
- Jennifer Keiser
Cigarette Smoking
Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos
The parent project (1R21CA253600-01, R21 phase: 9/1/2020-8/31/2022, R33 phase: 9/1/2022-8/31/2025) aims to adapt and evaluate the efficacy of our theoretically and empirically based mobile health (mHealth) technology to help…
- Trial name
- SurvLaos (NCT05253573)
- Testing
- Nicotine patch, Self-help materials (to support smoking cessation), Smartphone-based automated treatment for smoking cessation
- Where
- 2 sites in Laos
- Volunteers
- 80 people
- Sponsor
- University of Oklahoma
Trichuriasis
Efficacy and Safety of IVM/ALB Co-administration
This study is a double-blind randomized clinical trial conducted with two settings in Africa and one in Asia, namely Côte d'Ivoire, Pemba (Zanzibar, Tanzania) and Lao PDR.
- Trial name
- NCT03527732
- Testing
- Albendazole, Albendazole and Ivermectin
- Where
- 3 sites in Côte d’Ivoire, Laos and 1 more
- Volunteers
- 1,673 people
- Sponsor
- Jennifer Keiser